Mereo Biopharma

MREO
0.26005.45% ( -0.0150 )
Closed: Nov 20, 16:00:00 (EDT)

Valuation

Current ValuationThe current P/E ratio is -1.54, within the reasonable range, cheaper than 52.69% of the time in the past 1 years, and the industry ranks 276/607, the industry Median -1.55.

-1.54xP/E
Stock price$0.26Earnings per share$-0.17

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-53.45x162.72%$206.43B
MRNAUSModerna
-27.91x0.44%$77.85B
CSLLYUSCSL Limited
-24.06x--$62.05B
NTRAUSNatera
-240.69x4.11%$39.64B
RVMDUSRevolution Medicines
-18.47x38.62%$34.55B
INSMUSInsmed
-51.20x74.85%$31.01B
ROIVUSRoivant Sciences
-81.33x102.68%$28.01B
BNTXUSBioNTech SE
-11.86x26.17%$20.07B
BBIOUSBridgebio Pharma
-25.01x31.00%$14.81B
BMRNUSBioMarin Pharma
-612.14x55.46%$11.70B
KYMRUSKymera Therapeutics
-27.44x8.74%$9.59B
SYREUSSpyre Therapeutics
-39.63x59.92%$8.88B
MDGLUSMadrigal Pharma
-56.65x86.62%$8.81B
PCVXUSVaxcyte
-7.63x42.32%$8.77B
PRAXUSPraxis Precision Medicines
-23.36x0.35%$8.40B
SMMTUSSummit Therapeutics
-9.53x24.09%$7.94B
RYTMUSRhythm Pharma
-39.28x51.65%$7.79B
ALKSUSAlkermes
-21,515.32x133.70%$7.55B
CGONUSCG oncology
-29.89x41.23%$7.10B
CYTKUSCytokinetics
-9.09x8.68%$7.07B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.